Study on Synthesis, Antiproliferative Properties, Immunomodulatory Effects, and Anti‐Breast Cancer Activity of New Δ 2 ‐Pyrazoline‐1 H ‐1,2,3‐Triazole Derivatives
Chemistry & Biodiversity · 2026
DOI: 10.1002/cbdv.71611 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2026. Verfasst von Sadiq Noor Khan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Natural and Medical Sciences Research Center, University of Nizwa, Nizwa, Oman. Hauptthemen laut MEDLINE: Triazoles, Antineoplastic Agents, Pyrazoles, Breast Neoplasms. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Ministry of Higher Education, Research and Innovation.
Abstract (Originalsprache)
In the current work, a new series of novel Δ 2 ‐pyrazoline‐1 H ‐1,2,3‐triazole derivatives ( 6a‐6j and 7a‐7f ) were synthesized, followed by in situ biological evaluation to assess their antiproliferative and immunomodulatory potential against breast cancer cells (MDA‐MB‐231 and MCF‐7), HUVECs, and PBMCs. The compounds demonstrated antiproliferative effects with IC 50 values ranging from 116.92 to 549.73 µM. Seven compounds ( 6c , 6f , 6h , 6i , 7b , 7e , and 7f ) exhibited promising antiproliferative activities with IC 50 values below 140 µM in both MDA‐MB‐231 and MCF‐7 cancer cell lines. Compound 7f demonstrated the highest antiproliferative effect with IC 50 values of 116.92 µM in MDA‐MB‐231 and 124.72 µM in MCF‐7, with an acceptable cytotoxicity profile in normal HUVEC cells (IC 50 = 208.41 µM); thus, immunomodulatory effects of 7f on checkpoint signaling were further evaluated. Compound 7f showed a dose‐dependent increase of TIGIT, PD‐1, and LAG‐3 expression in CD3 + T cells. These changes may enhance responsiveness to checkpoint‐targeted therapies while reflecting complex regulation of T‐cell function. In silico target fishing and molecular docking reflect calpain as a probable target for 7f , while DFT analysis indicates electrophilic and nucleophilic positions within 7f may help its interaction with the target. Molecular dynamics (MD) simulation supports strong binding of 7f with binding energy (−22.259 ± 4.71 kcal mol −1 ).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Natural and Medical Sciences Research Center, University of Nizwa, Nizwa, Oman.
- Department of Chemical and Biological Engineering, College of Engineering, Korea University, Seongbuk-gu, Republic of Korea.
- Organic Chemistry, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
ORCID-Profile: Ebrahimi Amirhossein, Saeed Mohammadi, Satya Kumar Avula, Sobia Ahsan Halim, Najeeb Ur Rehman, Shaikh Mizanoor Rahman, Ajmal Khan, René Csuk, Ali Rostami, Ahmed Al-Harrasi
Förderung
- Ministry of Higher Education, Research and Innovation
Zitieren
APA
Khan, S. N., Moghtaderi, H., Amirhossein, E., Mohammadi, S., Avula, S. K., Halim, S. A., Duran, S., Rehman, N. U., Rahman, S. M., Khan, A., Csuk, R., Rostami, A., & Al-Harrasi, A. (2026). Study on Synthesis, Antiproliferative Properties, Immunomodulatory Effects, and Anti‐Breast Cancer Activity of New Δ 2 ‐Pyrazoline‐1 H ‐1,2,3‐Triazole Derivatives. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.71611
Vancouver
Khan SN, Moghtaderi H, Amirhossein E, Mohammadi S, Avula SK, Halim SA, et al. Study on Synthesis, Antiproliferative Properties, Immunomodulatory Effects, and Anti‐Breast Cancer Activity of New Δ 2 ‐Pyrazoline‐1 H ‐1,2,3‐Triazole Derivatives. Chemistry & Biodiversity. 2026. doi:10.1002/cbdv.71611
BibTeX
@article{Khan2026,
author = {Khan, Sadiq Noor and Moghtaderi, Hassan and Amirhossein, Ebrahimi and Mohammadi, Saeed and Avula, Satya Kumar and Halim, Sobia Ahsan and Duran, Shahid and Rehman, Najeeb Ur and Rahman, Shaikh Mizanoor and Khan, Ajmal and Csuk, René and Rostami, Ali and Al-Harrasi, Ahmed},
title = {Study on Synthesis, Antiproliferative Properties, Immunomodulatory Effects, and Anti‐Breast Cancer Activity of New Δ 2 ‐Pyrazoline‐1 H ‐1,2,3‐Triazole Derivatives},
journal = {Chemistry & Biodiversity},
year = {2026},
doi = {10.1002/cbdv.71611}
}
EUVIMED